Contec Bio: Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) Initiates Phase I Clinical Trial

Contec Bio announced that the four-valent influenza virus split vaccine (MDCK cell) developed by the company and Lanzhou Bailing Biological Technology Co., Ltd. has completed Phase I clinical trial preparation work, has initiated Phase I clinical trials, and recently successfully enrolled the first subject.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin